MASI logo

Masimo Corporation Stock Price

NasdaqGS:MASI Community·US$9.4b Market Cap
  • 1 Narratives written by author
  • 1 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

MASI Share Price Performance

US$178.64
28.73 (19.16%)
US$180.00
Fair Value
US$178.64
28.73 (19.16%)
0.8% undervalued intrinsic discount
US$180.00
Fair Value
Price US$178.64
AnalystConsensusTarget US$180.00

MASI Community Narratives

·
Fair Value US$180 0.8% undervalued intrinsic discount

Advanced Monitoring And Telehealth Will Expand Global Markets

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
US$180
0.8% undervalued intrinsic discount
Revenue
6.49% p.a.
Profit Margin
16.58%
Future PE
33.84x
Price in 2029
US$223.74

Trending Discussion

Updated Narratives

MASI logo

MASI: Cash Deal Terms And Legal Outcomes Will Shape Future Returns

Fair Value: US$180 0.8% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Solid track record with adequate balance sheet.

1 Risk
2 Rewards

Masimo Corporation Key Details

US$1.6b

Revenue

US$598.0m

Cost of Revenue

US$960.5m

Gross Profit

US$743.7m

Other Expenses

US$216.8m

Earnings

Last Reported Earnings
Apr 04, 2026
Next Reporting Earnings
n/a
4.14
61.63%
13.91%
57.3%
View Full Analysis

About MASI

Founded
1989
Employees
2200
CEO
Catherine Szyman
WebsiteView website
www.masimo.com

Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

Recent MASI News & Updates

Narrative Update May 12

MASI: Cash Deal Terms And Legal Outcomes Will Shape Future Returns

Analysts held Masimo's fair value estimate steady at $180 per share, with only small tweaks to discount rate, growth, margin, and P/E assumptions as they factor in the agreed $180 per share cash acquisition by Danaher and recent shifts in research coverage and ratings. Analyst Commentary Recent research coverage on Masimo has shifted toward a more balanced stance after the agreed cash acquisition by Danaher at US$180 per share, with several firms resetting ratings and price targets around the deal terms.

Recent updates

No updates